Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Pre-Clinical Teaching Building, Suite 211, 725 N Wolfe Street, Baltimore, MD, 21205, USA.
Curr HIV/AIDS Rep. 2018 Apr;15(2):136-146. doi: 10.1007/s11904-018-0383-2.
This review will outline the multilevel effects of biological sex on HIV acquisition, pathogenesis, treatment response, and prospects for cure. Potential mechanisms will be discussed along with future research directions.
HIV acquisition risk is modified by sex hormones and the vaginal microbiome, with the latter acting through both inflammation and local metabolism of pre-exposure prophylaxis drugs. Female sex associates with enhanced risk for non-AIDS morbidities including cardiovascular and cerebrovascular disease, suggesting different inflammatory profiles in men and women. Data from research on HIV cure points to sex differences in viral reservoir dynamics and a direct role for sex hormones in latency maintenance. Biological sex remains an important variable in determining the risk of HIV infection and subsequent viral pathogenesis, and emerging data suggest sex differences relevant to curative interventions. Recruitment of women in HIV clinical research is a pathway to both optimize care for women and to identify novel therapeutics for use in both men and women.
本文将概述生物性别对 HIV 感染、发病机制、治疗反应和治愈前景的多层次影响。讨论潜在机制,并提出未来的研究方向。
性激素和阴道微生物组会改变 HIV 的感染风险,后者通过炎症和暴露前预防药物的局部代谢发挥作用。女性感染 HIV 的风险更高,包括心血管和脑血管疾病等非艾滋病相关疾病,这表明男性和女性的炎症特征不同。HIV 治愈研究的数据表明,病毒储存库动力学存在性别差异,性激素在潜伏期维持中起直接作用。生物性别仍然是决定 HIV 感染风险和随后病毒发病机制的重要变量,新出现的数据表明,与治疗干预相关的性别差异。招募女性参与 HIV 临床研究是优化女性护理和确定适用于男性和女性的新型治疗方法的途径。